Search - tctmd.com

Displaying 1 - 20 of 44

Sort: Relevancy | Date

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

L.A. McKeown

May 14, 2020

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

L.A. McKeown

November 22, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

Caitlin E. Cox

August 15, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

Advertisement

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Routine IVUS in Peripheral Interventions Supported by Small RCT

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

Recovered Paclitaxel PAD Data Shift the Mortality Picture

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content